Heron Therapeutics, Inc. (NASDAQ:HRTX) – Research analysts at Oppenheimer Holdings issued their Q3 2017 EPS estimates for Heron Therapeutics in a research report issued to clients and investors on Monday. Oppenheimer Holdings analyst D. Archila forecasts that the biotechnology company will post earnings per share of ($0.83) for the quarter. Oppenheimer Holdings has a “Buy” rating and a $27.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ Q4 2017 earnings at ($0.88) EPS, FY2017 earnings at ($3.49) EPS, Q1 2018 earnings at ($0.87) EPS, Q2 2018 earnings at ($0.81) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.49) EPS, FY2018 earnings at ($2.81) EPS, FY2019 earnings at ($0.55) EPS, FY2020 earnings at $1.46 EPS and FY2021 earnings at $3.30 EPS.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/02/analysts-issue-forecasts-for-heron-therapeutics-inc-s-q3-2017-earnings-hrtx.html.
HRTX has been the subject of several other reports. Noble Financial reiterated a “buy” rating and set a $24.00 price objective on shares of Heron Therapeutics in a research report on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Monday, September 25th. Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, July 12th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Cowen and Company set a $40.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the stock. Heron Therapeutics presently has a consensus rating of “Buy” and an average target price of $28.36.
A number of large investors have recently made changes to their positions in HRTX. Janus Henderson Group PLC acquired a new stake in Heron Therapeutics during the 2nd quarter valued at $78,134,000. Vanguard Group Inc. raised its stake in Heron Therapeutics by 40.2% during the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock valued at $28,127,000 after purchasing an additional 537,563 shares during the period. State Street Corp raised its stake in Heron Therapeutics by 30.7% during the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after purchasing an additional 420,113 shares during the period. Point72 Asset Management L.P. acquired a new stake in Heron Therapeutics during the 1st quarter valued at $2,002,000. Finally, Credit Suisse AG raised its stake in Heron Therapeutics by 329.8% during the 1st quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 110,539 shares during the period.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.